181 related articles for article (PubMed ID: 16314433)
21. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
22. Adenovirus E1A, not human papillomavirus E7, sensitizes tumor cells to lysis by macrophages through nitric oxide- and TNF-alpha-dependent mechanisms despite up-regulation of 70-kDa heat shock protein.
Miura TA; Morris K; Ryan S; Cook JL; Routes JM
J Immunol; 2003 Apr; 170(8):4119-26. PubMed ID: 12682242
[TBL] [Abstract][Full Text] [Related]
23. Expression of NKG2D and its ligand in mouse heart allografts may have a role in acute rejection.
Feng L; Ke N; Ye Z; Guo Y; Li S; Li Q; Li Y
Transplant Proc; 2009 Dec; 41(10):4332-9. PubMed ID: 20005394
[TBL] [Abstract][Full Text] [Related]
24. The NKG2D receptor: sensing stressed cells.
López-Larrea C; Suárez-Alvarez B; López-Soto A; López-Vázquez A; Gonzalez S
Trends Mol Med; 2008 Apr; 14(4):179-89. PubMed ID: 18353724
[TBL] [Abstract][Full Text] [Related]
25. The activating immunoreceptor NKG2D and its ligands are involved in allograft transplant rejection.
Kim J; Chang CK; Hayden T; Liu FC; Benjamin J; Hamerman JA; Lanier LL; Kang SM
J Immunol; 2007 Nov; 179(10):6416-20. PubMed ID: 17982029
[TBL] [Abstract][Full Text] [Related]
26. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
27. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
28. A transmembrane-anchored rat RAE-1-like transcript as a ligand for NKR-P2, the rat ortholog of human and mouse NKG2D.
Savithri B; Khar A
Eur J Immunol; 2006 Jan; 36(1):107-17. PubMed ID: 16323246
[TBL] [Abstract][Full Text] [Related]
29. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
30. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
Oppenheim DE; Roberts SJ; Clarke SL; Filler R; Lewis JM; Tigelaar RE; Girardi M; Hayday AC
Nat Immunol; 2005 Sep; 6(9):928-37. PubMed ID: 16116470
[TBL] [Abstract][Full Text] [Related]
31. Activating receptor NKG2D targets RAE-1-expressing allogeneic neural precursor cells in a viral model of multiple sclerosis.
Weinger JG; Plaisted WC; Maciejewski SM; Lanier LL; Walsh CM; Lane TE
Stem Cells; 2014 Oct; 32(10):2690-701. PubMed ID: 24898518
[TBL] [Abstract][Full Text] [Related]
32. Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition.
Mamessier E; Sylvain A; Bertucci F; Castellano R; Finetti P; Houvenaeghel G; Charaffe-Jaufret E; Birnbaum D; Moretta A; Olive D
Cancer Res; 2011 Nov; 71(21):6621-32. PubMed ID: 21937679
[TBL] [Abstract][Full Text] [Related]
33. CD4(+) NKG2D(+) T cells induce NKG2D down-regulation in natural killer cells in CD86-RAE-1ε transgenic mice.
Lin Z; Wang C; Xia H; Liu W; Xiao W; Qian L; Jia X; Ding Y; Ji M; Gong W
Immunology; 2014 Mar; 141(3):401-15. PubMed ID: 24708417
[TBL] [Abstract][Full Text] [Related]
34. NKG2D and cytotoxic effector function in tumor immune surveillance.
Hayakawa Y; Smyth MJ
Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
[TBL] [Abstract][Full Text] [Related]
35. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
36. E1A oncogene expression level in sarcoma cells: an independent determinant of cytolytic susceptibility and tumor rejection.
Cook JL; Wilson BA; Wolf LA; Walker TA
Oncogene; 1993 Mar; 8(3):625-35. PubMed ID: 8437846
[TBL] [Abstract][Full Text] [Related]
37. Role of p300-family proteins in E1A oncogene induction of cytolytic susceptibility and tumor cell rejection.
Cook JL; Krantz CK; Routes BA
Proc Natl Acad Sci U S A; 1996 Nov; 93(24):13985-90. PubMed ID: 8943047
[TBL] [Abstract][Full Text] [Related]
38. Up-regulation of NKG2D ligands by AML cells to increase sensitivity to NK cells: the tumour might strike back. Comment on "differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis" by Rohner et al. [Leuk Res 2007;31:1393-402].
Zimmer J; Michel T; Andrès E; Hentges F
Leuk Res; 2008 Apr; 32(4):676-7. PubMed ID: 17920678
[No Abstract] [Full Text] [Related]
39. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
André P; Castriconi R; Espéli M; Anfossi N; Juarez T; Hue S; Conway H; Romagné F; Dondero A; Nanni M; Caillat-Zucman S; Raulet DH; Bottino C; Vivier E; Moretta A; Paul P
Eur J Immunol; 2004 Apr; 34(4):961-71. PubMed ID: 15048706
[TBL] [Abstract][Full Text] [Related]
40. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis.
Rohner A; Langenkamp U; Siegler U; Kalberer CP; Wodnar-Filipowicz A
Leuk Res; 2007 Oct; 31(10):1393-402. PubMed ID: 17391757
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]